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Background: We describe the first case of a patient with factitious disorder who closely simulated a primary
immune deficiency disorder – Common Variable Immune Deficiency (CVID), by surreptitiously ingesting
non-steroidal anti-inflammatory agents.
Case description: He was treated with several expensive and potentially dangerous drugs before the diagnosis
was established through collateral information. In retrospect he did not meet the proposed new criteria for CVID.
These criteria may prove useful in distinguishing cases of CVID from secondary hypogammaglobulinemia.
Conclusion: It is imperative clinicians recognise patients with factitious disorder at the earliest opportunity to
prevent iatrogenic morbidity and mortality.
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Patients with factitious disorder have feigned a tremen-
dous variety of physical and mental illnesses and it can
be very difficult for clinicians to distinguish between real
and fabricated symptoms. Therefore, most specialists in
the field of factitious disorders, such as psychosmatic or
consult-liaison psychiatrists look for a pattern of behav-
iour rather than a single triggering finding to make the
diagnosis. For specialists who do not knowingly encounter
these patients, the correct diagnosis of factitious disorder
may never be made because it is not even considered.
People with factitious disorder deceive clinicians in order
to be treated as patients. Severe cases of factitious disorder
are sometimes referred to as Munchausen syndrome [1].
The condition may involve the exaggeration or false
reports of symptoms of an actual underlying disease or
the complete fabrication of subjective complaints, phys-
ical exam and/or laboratory findings. By definition, these
patients are not seeking a secondary gain such as money,
time off work or recreational drugs. The focus of these
patients is to be cared for and for most of these patients* Correspondence: rohana@adhb.govt.nz
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distribution, and reproduction in any mediumit is probably a maladaptive coping mechanism to man-
age their emotional distress. Simulating the disease can
be painful and even dangerous for these patients. Facti-
tious behaviour often results in unnecessary medical or
surgical interventions that carry risks for the health or
even the life of the patient.
Studies suggest these patients account for 0.2-1.0% of
hospital admissions but this may be an underestimate as
the disorder is often unsuspected [2]. A study from the
NIH [3] found that patients with factitious fevers accounted
for 9.3% of patients referred to a tertiary hospital for fever
of unknown origin. Patients with factitious disorder have
presented for investigation of secondary immunological
disorders including HIV/AIDS [4] and abscesses from
self-injection of fecal material [5]. Two cases of suspected
Munchausen syndrome by proxy were described in a case
series of children with intestinal pseudo obstruction and
hypogammaglobulinemia [6]. We present the first known
case of a patient with factitious disorder who was treated
for severe hypogammaglobulinemia and Common Variable
Immune Deficiency (CVID).
Case report
A male in his 30s was seen as an outpatient at a large
metropolitan hospital with a seven month history of antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 2 Capsule endoscopy showing extensive enteritis of
the jejunum.
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chronic diarrhea. Further investigations confirmed the
presence of severe anemia (Hb 40 g/l, nr >125) and pro-
found hypoalbuminemia (23 g/l, nr >40). On initial pres-
entation he minimized his medical history and noted he
had conceived a child with in-vitro fertilization 2 years
prior to his symptoms.
Gastroscopy showed duodenal atrophy consistent with
celiac disease. Duodenal ulceration was also noted
(Figure 1). The biopsies showed villous atrophy but ab-
sence of a lymphocyte infiltrate. A diagnosis of presump-
tive celiac disease was made in spite of the absence
serological markers. He was placed on a gluten free diet.
His anemia was thought to be due to iron malabsorption
and he was treated with a blood transfusion and an infu-
sion of parenteral iron. He was taking nonsteroidal anti-
inflammatory drugs (NSAIDS) for a knee injury and was
advised to discontinue these.
A colonoscopy was normal. A CT scan of the abdomen
did not reveal malignancy. He had a markedly elevated
fecal calprotectin (>500 μg/g feces, nr <50) indicating
ongoing small intestine inflammation. His ESR and CRP
were elevated. There was no improvement in his clinical
state with ongoing anemia and lethargy despite a gluten
free diet and reporting no further NSAID use.
Capsule endoscopy was undertaken which showed ex-
tensive, severe ulceration of the small intestine (Figure 2).
He was thought to have concomitant Crohn’s disease. His
ASCA antibodies were negative. In the context of clinical
decline despite gluten free diet, the patient’s confirmation
of NSAID withdrawal and extensive small bowel ulcer-
ation on capsule study, he was treated with high dose oral
prednisone, with temporary improvement of his symp-
toms. Azathioprine was added as a steroid sparing agent.
His immunoglobulins were subsequently measured, re-
vealing profound hypogammaglobulinemia. His IgG wasFigure 1 Duodenal biopsy showing ulceration from
NSAID abuse.1.5 g/l (nr> 8) with reduced IgA of 0.4 g/l (nr> 0.8) but
IgM just in the normal range at 0.4 g/l (nr> 0.4). He was
referred to the clinical immunology service at Auckland
Hospital with suspected Common Variable Immune
Deficiency (CVID) with predominant gut involvement.
His fecal alpha 1-antitrypsin level was elevated consistent
with protein losing enteropathy. The absence of sero-
logical markers of his gut disease was thought to be due
to the humoral immune defect even though vaccine re-
sponses to H. influenzae type B (0.44 μg/ml, protective
range >0.15) and tetanus toxoid (0.16 IU/ml protective
range >0.1) were preserved. He had low levels of diph-
theria antibodies and pneumococcal antibodies, which
may have reflected absence of recent immunization. Vac-
cine challenge responses were not undertaken prior to
IVIG treatment, because of the severity of the immune de-
fect. The major immunology results are shown in Table 1.
Personal history and review of computerized medical
records revealed a benign infectious history prior to the
current presentation. Repeat testing confirmed persistent
severe hypogammaglobulinemia. Immunophenotyping
showed normal numbers of B cells (12% of total lympho-
cytes) and the presence isotype switched memory B cells.
He was thought to have protein losing enteropathy sec-
ondary to CVID. He was commenced on high dose IVIG
but his serum IgG failed to increase to the normal range
(Figure 3). In spite of his immunosuppression his albu-
min remained at 23 g/l. The fecal calprotectin levels
remained markedly elevated indicating ongoing bowel
inflammation. The clinical immunology service consid-
ered the use of Infliximab for the refractory CVID-
associated enteritis.
Table 1 Summary of major immunology results
Serology Patient Reference interval
IgG 1.5 g/l >8 g/l
IgA 0.4 g/l >0.8 g/l
IgM 0.4 g/l >0.3 g/l
Tetanus antibodies 0.16 IU/ml >0.1 IU/ml
H. influenzae type
B antibodies
0.44 μg/ml >0.15 μg/ml
Diphtheria antibodies 0.01 IU/ml >0.1 IU/ml
Isohemagglutinins Present
Cell markers Patient Reference interval
CD4 498 × 106/l 500-1650 × 106/l
CD8 271 × 106/l 210-1200 × 106/l
CD3 794 × 106/l 780-2600 × 106/l
CD19 122 × 106/l 80-600 × 106/l
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cious about the atypical presentation and lack of re-
sponse to treatment. A bleeding time was prolonged
raising the possibility of NSAID abuse. Careful review of
gastric biopsies revealed micro ulcerations. These findings
were discussed but both the patient and his wife offered
repeated assertions that he had not taken any NSAIDs
or similar agents for several months. Subsequent to
that appointment however, his family discovered numer-
ous concealed packets of an Ibuprofen/codeine combin-
ation and brought this to the attention of the clinical staff.
When confronted with this information, the patient
admitted surreptitious use of NSAIDS throughout the
preceding year. It was felt by both the gastroenterology
and immunology teams that all his symptoms were due
to small bowel enteropathy caused by NSAID abuse. HisFigure 3 IgG levels before and during IVIG treatment.immunosuppression and immunoglobulin infusions were
discontinued and per his family, his symptoms abated.
Although the patient declined psychiatric evaluation
or outpatient therapy, collateral information elicited a
complicated history. His family psychiatric history in-
cluded bipolar disorder and addiction. In terms of his
social history, the patient had undergone more than 6
career changes, including biochemistry and chemistry
training as he had indicated at one point that he planned
to pursue a career in medicine. According to his family, he
frequently read medical texts and at times he described
himself as a “pre-med” or a medical student although he
had no formal medical training. He also reportedly was
prone to self-medication that extended to significant use
of recreational drugs such as marijuana, peyote and other
hallucinogens that he felt “sharpened his understanding”.
In addition to illegal drugs, family reported that he
used caffeine pills and energy drinks on a daily basis. His
social history also included ongoing issues with financial
stressors. His personal psychiatric history included sex-
ual abuse as a child and a history of at least one known
suicide attempt. While he was noted to be impulsive, he
was not known to have received a diagnosis or treatment
for bipolar disorder. He had been diagnosed and treated
for depression. He has not returned for follow up.
Discussion
This patient illustrates the difficulty in identifying and
treating patients with factious disorder. Given the severity
of his anemia and bowel ulceration in the setting of the
poor response to treatment, a severe gastrointestinal variant
of CVID was suspected. His hypogammaglobulinemia
proved relatively resistant to treatment with IVIG (Figure 3).
He was on the verge of being treated with biological agents
including Infliximab when his wife contacted the clinical
staff on the discovery of surreptitious NSAID use. Apart
from the expense, biological agents expose patients to
serious risks including death from infections and ma-
lignancy. The self-induced gastrointestinal disease also
had the potential for a fatal outcome if he had suf-
fered bowel perforation. Deaths from the self-induced
disorder or its treatment have been described in facti-
tious disorder [7,8].
Patients with factitious disorders frequently cause
diagnostic confusion and anxiety in clinicians when they
fail to improve as expected. They cause anxiety as the
treating clinician becomes increasingly concerned about
a missed diagnosis and the risk to professional reputa-
tion. In some countries the risk of malpractice litigation
from a missed diagnosis adds another dimension to the
anxiety faced by clinicians, particularly surgeons [9].
This results in a cycle of more invasive and expensive in-
vestigations. When the deception is uncovered it can pro-
voke anger and frustration in treating clinicians. Many
Table 2 New diagnostic criteria for CVID
A. Must meet all major criteria
❖ Hypogammaglobulinemia: IgG below 5 g/L for adults
❖ No other cause identified for immune defect
❖ Age > 4 years
B. Clinical sequelae directly attributable to in vivo immune system
failure (ISF) (1 or more criteria)
❖ Recurrent, severe or unusual infections.
❖ Poor response to antibiotics
❖ Breakthrough bacterial infections in spite of prophylactic
antibiotics
❖ Infections in spite of immunization with the appropriate vaccine
e.g. HPV disease
❖ Bronchiectasis and/ or chronic sinus disease
❖ Inflammatory disorders or autoimmunity
C. Supportive laboratory evidence (3 or more criteria)
❖ Concomitant deficiency or reduction of IgA (< 0.8 g/l) and/or IgM
(< 0.4 g/l)
❖ Presence of B cells but reduced memory B cell subsets and/or
increased CD21 low subsets by flow cytometry
❖ IgG3 deficiency (< 0.2 g/l)
❖ Impaired vaccine responses compared to age-matched controls
❖ Transient responses to vaccines compared to age-matched
controls
❖ Absent isohemagglutinins (if not blood group AB)
❖ Serological support for autoimmunity in section B e.g. positive
Coombs test
❖ Sequence variations of genes predisposing to CVID e.g. TACI,
BAFFR, MSH5 etc
D. Presence of any one of relatively specific histological markers of
CVID (Not required for diagnosis but presence increases diagnostic
certainty)
❖ Lymphoid interstitial pneumonitis
❖ Granulomatous disorder
❖ Nodular regenerative hyperplasia of the liver
❖ Nodular lymphoid hyperplasia of the gut
❖ Absence of plasma cells on gut biopsy
Meeting criteria in categories ABC or ABD indicates probable CVID. Patients
meeting criteria ABC and ABD should be treated with IVIG/scIG. Patients
meeting criteria A alone, AB or AC or AD but not B, are termed possible CVID.
Some of these patients may need to be treated with IVIG/scIG. Patients with
levels of IgG >5 g/l, not meeting any other criteria are termed
hypogammaglobulinemia of uncertain significance (HGUS). A detailed review
of these criteria have been recently published [15].
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Borderline Personality Disorder [10]. With manipulative
behaviour, splitting between staff and idealization/denigra-
tion, these patients frequently cause significant dishar-
mony and loss of effectiveness in clinical teams [11].
During the course of investigation, three separate diag-
noses were entertained in our patient, Celiac disease,
Crohn’s disease and CVID. The unifying diagnosis was
thought to be CVID, as it is associated with both Crohn’s
disease and Celiac disease [12]. In this case, all three pos-
sible diagnoses were associated with atypical laboratory re-
sults. He did not have tissue transglutaminase, deamidated
gliaden peptide antibodies or HLA DQ2 or HLA DQ8 tis-
sue type, making celiac disease unlikely [13]. His histology
was not consistent with either Crohn’s disease or celiac
disease. When faced with unexpected laboratory results,
experienced clinicians are more inclined to believe the pa-
tient history in preference to laboratory results. It was the
occurrence of multiple inconsistent laboratory results and
failure to respond to treatment that eventually raised sus-
picion of NSAID abuse and factitious disorder, although
this was not confirmed until the patient’s family discov-
ered the hidden cache of NSAIDs [14]. It is very likely all
three diagnoses were a direct result of NSAID abuse.
As with most patients with factitious disorder, detailed
long-term follow up studies were not possible in this
case. The albumin increased to 28 g/l two weeks later,
after stopping all treatment, indicating improvement of
his enteritis.
With the benefit of hindsight CVID was very unlikely
in this patient. We have recently proposed new criteria
for the diagnosis of CVID (Table 2). In order to meet a
diagnosis of probable CVID patients must fulfil the
major criteria in category A. They must have symptoms
directly attributed to in vivo immune system failure (ISF)
(category B) and must have supportive laboratory evidence
(either category C or D criteria).
This patient did not meet category C or D criteria. Ana-
lysis of his serum immunoglobulin profile of reduced IgG
with preserved IgM was compatible with protein-losing en-
teropathy induced by NSAID abuse. His IgA level returned
to the normal range (0.8 g/l, nr > 0.8) just before he was
lost to follow up. The majority of CVID patients have a
concomitant reduction of IgA and or IgM in addition to re-
duced IgG levels [15]. Review of his blood transfusion re-
cords showed the presence of isohemagglutinins, indicating
preserved antibody responses to carbohydrates. The pres-
ence of normal numbers of switched memory B cell sub-
sets, although only undertaken on one occasion [16] makes
it is unlikely this patient had CVID. We did not measure
his IgG3 level and we did not undertake studies of suscepti-
bility genes for CVID [17].
He does not have category D criteria, which are the
presence of characteristic histological markers of CVID,such as granulomatous disease [18]. Retrospective review
of his intestinal biopsies confirmed the presence of
plasma cells, again making CVID very unlikely [15]. He
therefore does not meet the proposed new criteria for
CVID (Table 2) [15]. Application of these criteria will be
helpful in distinguishing CVID from cases of secondary
hypogammaglobulinemia.
Patients with factitious disorder are notoriously diffi-
cult to treat [19]. When their deception is uncovered, it
may provoke anger and patients frequently discharge
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seek treatment at other medical institutions (peregrin-
ation). There is usually lack of insight and these patients
rarely engage in on-going psychotherapy. Long-term fol-
low up studies of large cohorts of such patients are
absent from the medical and psychiatric literature [20].
Like many others, our patient had a link to the medical
profession [3].
This is the first factitious presentation of a well-
defined primary immune deficiency disorder, which we
have termed hypogammaglobulinemia factitia. Given the
uncanny resemblance to refractory CVID, factitious dis-
order was not suspected for several months. It is unclear
if this patient intended to simulate CVID.
His behaviour does not suggest drug addiction. Although
ibuprofen products in New Zealand often contain codeine,
it is unlikely that the non-disclosure of the NSAIDs was
due to substance abuse as there was no drug seeking be-
haviour or requests for more potent opiates. If codeine
abuse was main issue, there would have been no need
for the patient to use a combination drug. Furthermore
there was unquestioning willingness – even eagerness - to
undergo more invasive and dangerous treatments as has
been described in factitious disorder [1].
The family also reported that the patient avidly discussed
his ongoing medical care and his evolving medical diagno-
ses with great interest. He behaved as if he was a member
of the medical team because of his previous interest in
clinical training. In retrospect, it was noted that he would
routinely improve as an in-patient but never when he
was at home and that he sought out hospitalization. It
is suspected that he assumed the sick role as a maladap-
tive coping mechanism in the setting of poor emotional
coping skills and in the wake of multiple stressors, includ-
ing an unstable sense of self, family conflict and financial
stressors.
In this case, if the patient’s family had not found and
reported the NSAID use to the clinical team, it may not
have been discovered unless laboratory techniques such
as HPLC were deployed to detect NSAID use - despite
his denial [21]. Other papers have suggested that the
“single stripe sign” on colonscopy may indicate NSAID
abuse associated enteropathy, but the sensitivity and spe-
cificity of this is not reported and it was not noted in
this patient [22].
Patients with factitious disorder can present to any
branch of clinical medicine. However if the condition
is not considered by general or specialized clinical
services, the diagnosis will never be made and expen-
sive and dangerous investigations and treatments will be
inappropriately undertaken. Factitious disorder should
now be included in the differential diagnosis of severe
hypogammaglobulinemia/CVID. Application of the new
diagnostic criteria for CVID may allow distinction ofCVID from secondary causes of hypogammablobulinemia
with greater precision. By reporting this case, we hope that
other clinicians will benefit from the inadvertent discovery
of this patient’s disorder.
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